Benzinga · Jul 9, 2026
CollPlant Biotechnologies Files Prospectus For Offering 31.047M Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1631487/000121390026076733/ea0297371-f3_collplant.htm
CL
NASDAQ · CLGN
CollPlant Biotechnologies Ltd.
Healthcare · Biotechnology
$0.31
Down-$0.01 (-1.66%)
Updated Aug 19, 2026, 4:43 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 23.78M
- P/E ratio
- -1.96
- Dividend yield
- 0.00%
- 52-week range
- $0.27 – $3.18
- Volume
- 72.31K
- Avg. volume
- 99.32K
Price performance
CLGN price history
1M range · 21 trading sessions · Daily adjusted prices
CLGN closed at $0.31 after 21 trading sessions, down 1.75% for the selected period.
- Last close
- $0.31
- Period change
- -1.75%
- Period low
- $0.27
- Period high
- $0.34
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $0.31 | $0.3148 | $0.2787 | $0.3144 | 72.31K |
| Aug 17, 2026 | $0.3003 | $0.3198 | $0.2955 | $0.3197 | 16.1K |
| Aug 14, 2026 | $0.31 | $0.3394 | $0.3001 | $0.3297 | 70.82K |
| Aug 13, 2026 | $0.3126 | $0.3276 | $0.2954 | $0.3186 | 51.18K |
| Aug 12, 2026 | $0.31 | $0.3309 | $0.2953 | $0.3193 | 62.74K |
| Aug 11, 2026 | $0.3313 | $0.3313 | $0.29 | $0.295 | 353.3K |
| Aug 10, 2026 | $0.346 | $0.3475 | $0.30 | $0.3249 | 173.53K |
| Aug 7, 2026 | $0.346 | $0.35 | $0.3098 | $0.3388 | 45.44K |
| Aug 6, 2026 | $0.3164 | $0.35 | $0.2896 | $0.3307 | 140.51K |
| Aug 5, 2026 | $0.3189 | $0.3283 | $0.28 | $0.3101 | 51.72K |
| Aug 4, 2026 | $0.3243 | $0.3243 | $0.2868 | $0.2868 | 20.24K |
| Aug 3, 2026 | $0.2828 | $0.3189 | $0.2786 | $0.318 | 58.45K |
| Jul 31, 2026 | $0.2999 | $0.3099 | $0.2699 | $0.2728 | 51.48K |
| Jul 30, 2026 | $0.322 | $0.3399 | $0.2802 | $0.2999 | 28.85K |
| Jul 29, 2026 | $0.32 | $0.3507 | $0.3008 | $0.312 | 15.95K |
| Jul 28, 2026 | $0.339 | $0.339 | $0.3007 | $0.3278 | 13.74K |
| Jul 27, 2026 | $0.341 | $0.3491 | $0.305 | $0.3189 | 28.91K |
| Jul 24, 2026 | $0.3242 | $0.3302 | $0.31 | $0.3148 | 7.14K |
| Jul 23, 2026 | $0.3262 | $0.34 | $0.31 | $0.3124 | 10.95K |
| Jul 22, 2026 | $0.3325 | $0.3399 | $0.3013 | $0.32 | 8.13K |
| Jul 21, 2026 | $0.31 | $0.3435 | $0.3014 | $0.32 | 14.87K |
Latest CLGN news
The latest Smart Investors Daily articles mentioning CLGN.
Stock researchCompany · Overview
CLGN research
Overview
Company profile and research snapshot.
Company profile
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 6, 2026 | D. Boral Capital | Hold | — |
| Nov 28, 2025 | D. Boral Capital | Buy | — |
| Oct 20, 2025 | D. Boral Capital | Buy | — |
| Sep 16, 2025 | D. Boral Capital | Buy | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jun 30, 2026
CollPlant Biotechnologies Commences ~$2.6M Offering Of Ordinary Share, Warrants
CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical
Yahoo · Feb 26, 2026
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market.
Benzinga · Feb 26, 2026
CollPlant Biotechnologies Announced Korean Patent Allowance Secured for Its Photocurable Dermal Filler
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
